No Data
Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Cautious Hold Rating on Revance Therapeutics Amid Ongoing Merger Uncertainties With Crown Laboratories
Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday
Revance Therapeutics Jumps After Crown Laboratories Tender Offer Extended Again
Stifel Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $6.66
Revance Therapeutics Analyst Ratings